Home » Authors » Brady Huggett

Brady Huggett

Articles

ARTICLES

Cell Therapeutics Starts NSCLC Phase III, Eyes One More In 2002

Oct. 8, 2002

By Brady Huggett

Cell Therapeutics Starts NSCLC Phase III, Eyes One More In 2002

Oct. 8, 2002

By Brady Huggett

Lilly Loans Isis $21M To Build Affinitac Manufacturing Space

Oct. 2, 2002

By Brady Huggett

Nastech Regains U.S. Rights For Nascobal From Schwarz

Oct. 2, 2002

By Brady Huggett

Lilly Loans Isis $21M To Build Affinitac Manufacturing Space

Oct. 2, 2002

By Brady Huggett

Nastech Regains U.S. Rights For Nascobal From Schwarz

Oct. 2, 2002

By Brady Huggett

IntraBiotics' Iseganan Fails To Reduce Mucositis In Phase III

Oct. 1, 2002

By Brady Huggett

IntraBiotics Pharmaceuticals Inc. stopped development of iseganan for mucositis following a Phase III failure. (BioWorld Today)

IntraBiotics' Iseganan Fails To Reduce Mucositis In Phase III

Oct. 1, 2002

By Brady Huggett

IntraBiotics Pharmaceuticals Inc. stopped development of iseganan for mucositis following a Phase III failure. (BioWorld Today)

Genome Therapeutics To Reduce Staff, Drop Early Research Efforts

Sep. 26, 2002

By Brady Huggett

Genome Therapeutics To Reduce Staff, Drop Early Research Efforts

Sep. 26, 2002

By Brady Huggett

View All Articles by Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...